• Colorectal disorders

Pentasa Generic Name & Formulations

General Description

Mesalamine 250mg, 500mg; controlled-rel caps.

Pharmacological Class


How Supplied

Caps 250mg—240; 500mg—120

Generic Availability

250mg (NO); 500mg (YES)

Pentasa Indications


Mildly to moderately active ulcerative colitis.

Pentasa Dosage and Administration


Swallow whole; may open caps and sprinkle entire contents onto applesauce or yogurt, consume immediately. 1g four times daily for up to 8 weeks.


Not established.

Pentasa Contraindications

Not Applicable

Pentasa Boxed Warnings

Not Applicable

Pentasa Warnings/Precautions


Sulfasalazine allergy. Discontinue if acute intolerance syndrome is suspected. Discontinue at the 1st signs/symptoms of severe cutaneous adverse reactions. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Nephrolithiasis. Ensure adequate hydration. Renal or hepatic impairment. History of renal disease. Assess renal function prior to and periodically during therapy. Discontinue if renal function deteriorates while on therapy. Elderly (monitor CBCs, platelets). Pregnancy. Nursing mothers: monitor infants.

Pentasa Pharmacokinetics

See Literature

Pentasa Interactions


Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk for blood disorders, bone marrow failure, and associated complications with azathioprine or 6-mercaptopurine and/or other drugs known to cause myelotoxicity. May cause elevated test results in measuring urinary normetanephrine; consider alternative assay.

Pentasa Adverse Reactions

Adverse Reactions

Diarrhea, headache, nausea, abdominal pain, dyspepsia, vomiting, rash; renal impairment, acute intolerance syndrome, hypersensitivity reactions, severe cutaneous adverse reactions (eg, SJS, TEN, DRESS, AGEP).

Pentasa Clinical Trials

See Literature

Pentasa Note

Not Applicable

Pentasa Patient Counseling

See Literature